Chip Davis Shares HDA’s 2024 Policy Priorities in Annual Chain Drug Review Column
With a presidential election on the horizon and policymakers working to develop solutions to challenges facing patients and providers, this year will be critical for pharmaceutical distributors and the healthcare industry. Looking to the next 12 months, HDA’s President and CEO Chip Davis provides key insights into the association’s 2024 policy priorities in his annual column, “Health Care Outlook,” published by Chain Drug Review.
According to Davis, issues of access and affordability will continue to be topics of conversation, as well as the importance of a strong and resilient pharmaceutical supply chain. He states:
HDA and our 37 pharmaceutical distributor members, the vital link between 1,500 manufacturers and approximately 330,000 pharmacies, providers and other sites of care, will stay engaged and eager to collaborate and convene with private- and public-sector stakeholders alike during another consequential year. In 2024, we will further demonstrate distributors’ expertise as a strong, clear voice for supply chain reliability, security, and ultimately, patient access to healthcare.
More information on HDA’s policy efforts can be found here.
Each year, “Health Care Outlook” features HDA’s perspective along with commentary on emerging trends and policy priorities from other sector stakeholders. Read Davis’ full column to learn more.